Multiple Sclerosis (MS) is a chronic demyelinating disease of the central nervous system for which there is currently no cure. Current therapies only target the inflammatory and immune components of MS, but remyelination of damaged axons appears to be an attractive therapeutic strategy. OPCs are precursor cells that have the potential to differentiate into mature oligodendrocytes, the cells responsible for producing myelin. Stimulating the recruitment of OPCs to areas of demyelination is a key step in initiating the remyelination process. The second step involves guiding the OPCs to mature into fully functional oligodendrocytes capable of producing myelin. This ensures that the regenerated myelin sheath is structurally and functionally effective.
Developing therapies that effectively promote remyelination is a significant area of research in the field of MS. Creative Bioarray is currently investigating diverse strategies to augment the recruitment and differentiation of oligodendrocyte progenitor cells (OPCs). These strategies encompass the utilization of growth factors, small molecules, and stem cell-based therapies.